Infect. Immun., 06 1997, 2160-2167, Vol 65, No. 6
Copyright © 1997, American Society for Microbiology

Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18(106- 138)-immunoglobulin G in whole blood

M Ogata, MF Fletcher, M Kloczewiak, PM Loiselle, EM Zanzot, MW Vermeulen and HS Warren
Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

The 18-kDa cationic protein CAP18 is an antimicrobial protein isolated from rabbit granulocytes that binds lipopolysaccharide (LPS) and inhibits many of its biological activities. We covalently coupled a synthetic peptide representing amino acids 106 to 138 of CAP18 to human immunoglobulin G (IgG) by using the heterobifunctional linker N- succinimidyl-3-(2-pyridyidithio)propionate. The ability of CAP18(106- 138)-IgG to bind and neutralize LPS in whole blood in the presence and absence of anticoagulants was studied. Both CAP18(106-138) and CAP18(106-138)-IgG significantly suppressed LPS-induced tumor necrosis factor (TNF) production in whole blood in the absence of anticoagulants. EDTA potentiated the ability of CAP18(106-138) and CAP18(106-138)-IgG to decrease LPS-induced TNF production in a dose- dependent manner. In contrast, heparin inhibited the ability of CAP18(106-138) and CAP18(106-138)-IgG to suppress LPS-induced TNF production. EDTA also enhanced LPS capture in a fluid-phase binding assay that utilizes magnetic anti-IgG beads to capture CAP18(106-138)- IgG (and bound [3H]LPS) in whole blood. In contrast, heparin inhibited the binding dose dependently. We conclude that CAP18(106-138)-IgG binds to and neutralizes LPS in whole blood in the absence of anticoagulants. Further studies of its protective efficacy in animal models are warranted. Caution should be used in interpreting assays that measure the binding and neutralization of LPS in whole blood in the presence of calcium-binding anticoagulants or heparin.

This article has been cited by other articles:

• Bocharov, A. V., Baranova, I. N., Vishnyakova, T. G., Remaley, A. T., Csako, G., Thomas, F., Patterson, A. P., Eggerman, T. L. (2004). Targeting of Scavenger Receptor Class B Type I by Synthetic Amphipathic {alpha}-Helical-containing Peptides Blocks Lipopolysaccharide (LPS) Uptake and LPS-induced Pro-inflammatory Cytokine Responses in THP-1 Monocyte Cells. J. Biol. Chem. 279: 36072-36082 [Abstract] [Full Text]  
• Ogata, M., Nandate, K., Kawasaki, T., Kawasaki, C., Ozaki, M., Shigematsu, A. (2004). A Platelet Activating Factor Receptor Antagonist Inhibits Cytokine Production in Human Whole Blood by Bacterial Toxins and Live Bacteria. Anesth. Analg. 98: 1767-1772 [Abstract] [Full Text]  
• Van Amersfoort, E. S., Van Berkel, T. J. C., Kuiper, J. (2003). Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. Clin. Microbiol. Rev. 16: 379-414 [Abstract] [Full Text]  
• Kawasaki, C., Kawasaki, T., Ogata, M., Nandate, K., Shigematsu, A. (2001). Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood : [Les isomeres de la ketamine suppriment la production de cytokine pro-inflammatoire induite par des superantigenes dans le sang complet humain]. Canadian J. Anesthesia 48: 819-823 [Abstract] [Full Text]  
• Kawasaki, T., Ogata, M., Kawasaki, C., Tomihisa, T., Okamoto, K., Shigematsu, A. (2001). Surgical Stress Induces Endotoxin Hyporesponsiveness and an Early Decrease of Monocyte mCD14 and HLA-DR Expression During Surgery. Anesth. Analg. 92: 1322-1326 [Abstract] [Full Text]  
• Kawasaki, T., Ogata, M., Kawasaki, C., Ogata, J.-i., Inoue, Y., Shigematsu, A. (1999). Ketamine Suppresses Proinflammatory Cytokine Production in Human Whole Blood In Vitro. Anesth. Analg. 89: 665-665 [Abstract] [Full Text]  
• Zhang, G.-H., Mann, D. M., Tsai, C.-M. (1999). Neutralization of Endotoxin In Vitro and In Vivo by a Human Lactoferrin-Derived Peptide. Infect. Immun. 67: 1353-1358 [Abstract] [Full Text]